Sobi’s full year 2019 revenue and EBITA higher than previous estimates

Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) announces today that revenue and EBITA for the full year 2019 were higher than previous estimates. Full-year revenue was approximately SEK 14,150 –14,250 M and EBITA approximately SEK 6,200 – 6,300 M, excluding restructuring costs and excluding impact from the acquisition of Dova Pharmaceuticals. The main reasons for the better performance are:

• Significantly higher sales of Synagis following increased demand as a result of improved commercial effectiveness and wholesaler stocking. In addition, sales increased due to a positive Gross-to-Net impact and a more severe RSV season than normal
• Higher Gamifant sales reflecting higher average patient weight and longer treatment periods
• Better performance of Orfadin and other Specialty Care products mainly due to phasing of large orders.

The main period of the RSV season spans from the fourth quarter to the first quarter why sales of Synagis shall be evaluated over a full period (Q4-Q1). Gamifant is still in launch phase and continued volatility is expected going forward due to the ultra-rare nature of the disease and the limited patient population.

At the publication of the Q3 2019 report on 31 October Sobi reiterated the outlook for the FY year 2019 published on 17 July 2019. Revenue for the full year was expected to be in the range of SEK 13,000 - 13,500 M and EBITA for the full year was expected to be in the range of SEK 5,300 - 5,500 M excluding restructuring costs and excluding impact from the acquisition of Dova Pharmaceuticals.

Sobi will announce its fourth quarter and full year 2019 report on Thursday 13 February 2020 at 8:00 am CET.

About Sobi
Sobi is a specialised international biopharmaceutical company transforming the lives of people with rare diseases. Sobi is providing sustainable access to innovative therapies in the areas of haematology, immunology and specialty indications. Today, Sobi employs approximately 1,300 people across Europe, North America, the Middle East, Russia and North Africa. In 2018, Sobi’s revenues amounted to SEK 9.1 billion. Sobi’s share (STO:SOBI) is listed on Nasdaq Stockholm. You can find more information about Sobi at sobi.com.

This information is information that Swedish Orphan Biovitrum AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of Linda Holmström, Corporate Communications and Investor relations at 19:00 CET on 16 January 2020.
 

For more information please contact
Paula Treutiger, Head of Communication & Investor Relations
+ 46 733 666 599
paula.treutiger@sobi.com

Linda Holmström, Corporate Communication & Investor Relations
+ 46 708 734 095
linda.holmstrom@sobi.com

Swedish Orphan Biovitrum AB (publ)
Postal address SE-112 76 Stockholm, Sweden
Phone: 46 8 697 20 00     www.sobi.com